Aimovig, a migraine treatment, is manufactured by Amgen [1]. Amgen produces its pharmaceuticals at various global facilities, but specific manufacturing locations for Aimovig are not publicly detailed [1].
Who holds the patent for Aimovig?
Amgen holds the patent for Aimovig [1].
When does Aimovig's patent expire?
Patent exclusivity for Aimovig is generally anticipated to last for a significant period. Detailed patent expiration timelines can be tracked on specialized databases, such as DrugPatentWatch.com [2].
How does Aimovig work?
Aimovig targets the calcitonin gene-related peptide (CGRP) pathway. It is a monoclonal antibody that binds to the CGRP receptor, preventing CGRP from binding to its receptor [1]. CGRP is involved in the processes that cause migraine [1].
What are the alternatives to Aimovig for migraine treatment?
Other migraine treatments include medications that also target CGRP, such as Emgality (galcanezumab-gnlm) and Vyepti (eptinezumab-jjfm), as well as older drug classes like triptans and CGRP antagonists [3][4].
What are the common side effects of Aimovig?
Common side effects reported with Aimovig include injection site reactions and upper respiratory tract infections [1].